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Ewing sarcoma (ES) is a rare aggressive tumor commonly seen in children and young adults that have a tendency toward early dissemination to the lungs, bone, and bone 
marrow and are responsive to chemotherapy and radiation therapy 
(RT). Late effects of ES therapy include the second cancers, a 
tragic outcome for survivors of such young age.
CASE REPORT
A 3-year-old child presented to the department of medical 
oncology with a right maxillary mass extending to the orbit. 
Hematological parameters were within normal range. A fine-
needle aspiration cytology was done which revealed a small round 
cell tumor. This was followed by a tru-cut biopsy of the mass which 
showed sheets of small round tumor cells with fine chromatin, 
inconspicuous nucleoli, and scant to moderate cytoplasm, 
many showing clearing. Occasional interspersed vessels with 
peritheliomatous pattern were also observed. The panel of round 
cell tumor immunohistochemistry (IHC) markers was run and 
revealed the membranous of CD99 and nuclear positivity of FLI-1 
antigen along with focal positivity of cytokeratin, while CD45, 
desmin, myeloperoxidase (MPO), myogenin, synaptophysin, 
and chromogranin were negative. Based on the morphology and 
typical IHC markers positivity, the final diagnosis of ES/primitive 
neuroectodermal tumor was offered.
After the complete metastatic workup, the patient was treated 
on non-metastatic Ewing family tumor chemotherapy protocol 
with intensity-modulated radiotherapy. The patient responded 
well after the initial treatment and was followed up regularly. 
When he came for his subsequent visits after 5 months, his 
complete blood counts revealed a high total leukocyte count, and 
the peripheral smear showed atypical cells resembling blasts up 
to 58%. His bone marrow aspirate smear showed blast around 
52%, the morphology of which did not permit a categorization of 
myeloid or lymphoid lineage.
The bone marrow aspiration and biopsy were reported 
as marrow infiltrated by hematolymphoid neoplasm. Flow 
cytometry findings and positivity for neuron enolase and MPO 
stain in blasts were consistent with acute myeloid leukemia 
(AML) with monocytoid differentiation with a small subset of 
blasts expressing cytoplasmic CD79a, CD22, and CD19. No other 
lymphoid markers showed positivity. Cytogenetic studies did not 
reveal any gross genetic abnormality except for a 6 bp insertion 
in the TAD2 domain of CEBPA. This probably represents a 
polymorphism.
Treatment for AML was instituted at our center, but after an 
initial response, his condition deteriorated and 3 months into 
therapy, he succumbed to secondary infections.
DISCUSSION
The second malignant neoplasms (SMNs) are generally defined 
as cancers which develop in patients with more than two 
distinct histologic types occurring at least 6 months after the 
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diagnosis of the initial malignancy [1]. Previous therapy, genetic 
susceptibility, and the type of the first cancer are known to be 
associated with the risk of an SMN among patients treated for 
a childhood cancer [2]. Independent of initial treatment and 
any familial cancer syndrome, a significantly increased risk of 
developing any SMN was observed after Hodgkin’s lymphoma, 
retinoblastoma, soft tissue sarcoma, and a malignant bone tumor 
as the first malignant neoplasm [2].
Treatment-related SMN in ES patients varies from soft 
tissue sarcomas in radiotherapy treated patients to hematological 
malignancies in patients treated with intensified chemotherapy 
regimens containing high-dose alkylators and epipodophyllotoxins, 
which are known to cause secondary leukemias [3]. Among the 
solid tumors, a report of British survivors suggests that the risk 
of bone tumor, especially osteosarcoma as SMN was higher 
after ES treatment than other childhood cancers followed by 
many other tumors such as retinoblastoma, neuroblastoma, 
neuroepithelioma, teratocarcinoma, germinoma, endometrial 
sarcoma, liposarcoma, spindle cell sarcoma, dermatofibrosarcoma, 
fibroscarcoma, undifferentiated sarcoma, malignant melanoma, 
anaplastic astrocytoma, breast cancer, clear cell adenocarcinoma, 
papillary thyroid cancer, renal cell carcinoma, malignant 
thymoma, palatal and parotid mucoepidermoid carcinoma, colon 
cancer, gastric adenocarcinoma, bronchioalveolar carcinoma, and 
small cell lung cancers [4-9].
Several of these solid tumors, SMNs occurred far from the 
radiation field or in patients who received no RT. They may 
have factors known to predispose to the development of multiple 
malignancies such as the familial form of retinoblastoma and 
neurofibromatosis. The most common hematologic SMN in 
literature was found to be AML/MDS, which comprises about 
60% of the cases while others being B-cell and T-cell lineage 
ALL, Hodgkin lymphoma, non-Hodgkin lymphoma, and 
multiple myeloma [9,10]. Literature review also mentioned that 
hematologic SMNs generally have a shorter latency period than 
solid tumor SMN [3] as seen in our case where the interval was 
<6 months.
The attributable cause for leukemogenesis was intensified 
chemotherapy which causes DNA damage to hematopoietic stem 
cells forming atypical blasts perpetuated by G-CSF supplemented 
along with the chemotherapy regime. There are also higher than 
Figure 1: Round cell tumour. H&amp;E, x200
Figure 2: Nuclear positivity of FLI-1. IHC, x200
Figure 3: Membrane positivity of CD99. IHC, x200
Figure 4: BMA showing atypical blasts like cells (Leishman stain, x200)
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expected rates of SMN not clearly related to treatment, suggesting 
that there must be mild to modest genetic contribution to the risk. 
Although ES is not a part of any clearcut cancer predisposition 
syndrome; these family of tumours have been shown to contain 
alterations in RB and p53 which are known to be mutated in 
hereditary RB and Li Fraumeni syndrome, respectively [11].
The role of pathologists is of utmost importance to 
differentiate the second malignancy from recurrence of the first 
malignancy or therapy-related changes, especially so in case 
of an equivocal morphological picture. ES survivors should be 
educated on the risk of SMN and followed up closely throughout 
their lifetime.
CONCLUSION
ES survivors are at significant risk for SMN, particularly sarcomas 
and other solid tumors in RT fields and for myeloid SMN after 
epipodophyllotoxin and alkylator therapy. In addition, the risk 
in these patients may be higher than in those treated for other 
childhood cancers, and it is likely related, in part, to ES therapy.
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